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Introduction {#sec1}
============

Myosins are a large and diverse family of molecular motors important for cell migration and motility. The human genome encodes 39 myosin genes, subdivided into 12 different classes ([@bib7], [@bib30]). Class 2 is the largest (13 genes). Ten of these are found exclusively in muscle. The remaining three encode the non-muscle (NM) myosin isoforms 2A, 2B, and 2C, which contribute to cell shape, adhesion, and cytokinesis ([@bib27], [@bib40]). Myosin isoforms in the remaining classes contribute to a wide range of functions, including organelle trafficking, membrane tethering, Golgi organization, actin organization, and actin polymerization ([@bib22]). Individual cell types only express a subset of myosin genes. Early studies have shown that ∼8--11 different myosin isoforms are co-expressed in epithelial cell lines, leukocytes, liver cells, and myoblasts ([@bib4], [@bib43]). Some myosin isoforms are expressed widely, whereas others (e.g., Myo7a and Myo3) are restricted to a small tissue subset ([@bib18], [@bib23]).

It has never been determined how variation in myosin expression profile between closely related cell types contributes to a variation in cellular phenotype. Modulating myosin expression could help to drive a cell toward a more migratory phenotype and, therefore, metastasis in cancer. Here we determined the myosin isoform expression profile in a range of prostate cell lines and in silico and then investigated four of the overexpressed myosin isoforms to uncover how each contribute to the more highly metastatic phenotype of PC-3 cells ([@bib31]).

Results {#sec2}
=======

Myo1b, Myo9b, Myo10, and Myo18a Are Overexpressed in More Highly Metastatic Cells {#sec2.1}
---------------------------------------------------------------------------------

We analyzed myosin expression for all 26 of the non-muscle myosin genes in the three most widely used prostate cancer cell lines: PC-3, DU145, and LNCaP ([@bib42]). PC-3 cells are considered to have a higher metastatic potential than LNCaP cells ([@bib1]). Class 2 muscle myosin isoforms were excluded because they are not expressed in non-muscle cells. We also analyzed a matched pair of normal (1535NP) and cancerous (1535CT) cell lines derived from the prostate of the same patient ([@bib12]).

A core of 12 myosin genes were expressed in all cell lines tested, as demonstrated by RT-PCR ([Table S1](#mmc1){ref-type="supplementary-material"}). However, DU145 cells additionally expressed two myosin isoforms, Myo7a and Myo3, normally only expressed in the cochlea, retina, testis, lung, and kidney ([@bib23]) or in the retina and pancreas ([@bib18]) respectively, and, therefore, we did not use these cells in further experiments, although, for completeness, the qPCR analysis on these cells is included ([Figure S1](#mmc1){ref-type="supplementary-material"}).

Expression levels of *MYO1B*, *MYO1D*, *MYO1E*, *MYO9B*, *MYO10*, and *MYO18A* were significantly higher in PC-3 than in LNCaP cells by qPCR ([Figure 1](#fig1){ref-type="fig"}A). *MYO1B* and *MYO10* expression levels were also significantly higher in 1535CT than in 1535NP cells ([Figure 1](#fig1){ref-type="fig"}B). An in silico analysis ([Figure 1](#fig1){ref-type="fig"}C) showed that *MYO1B*, *MYO1D*, and *MYO10* levels were significantly higher in metastatic tumors than in benign tissue, suggesting that this trend is also found in vivo. *MYO1E* and *MYO18A* expression levels were also higher in 1535CT cells compared with 1535NP cells, although this difference was not significant, and the in silico analysis did not show any significant differences in expression ([Figure 1](#fig1){ref-type="fig"}C). However, the expression of *MYO18A* or *MYO1E* may be upregulated in some tumors. *MYO6* expression levels were significantly lower in PC-3 cells compared with LNCaP ([Figure 1](#fig1){ref-type="fig"}A), lower in 1535CT than in 1535NP cells ([Figure 1](#fig1){ref-type="fig"}B), and highest in localized medium-grade tumors ([Figure 1](#fig1){ref-type="fig"}C), as reported earlier ([@bib19], [@bib32]). *MYO9B* expression levels were increased in tumors compared with benign tissues ([Figure 1](#fig1){ref-type="fig"}C). Levels of *MYH9*, the only non-muscle myosin 2 gene we found to be expressed in prostate cancer cells, did not change at the mRNA level ([Figure 1](#fig1){ref-type="fig"}A) between LNCaP and PC-3 cells or between normal, tumor, or metastatic samples in the in silico analysis. Western blotting for Myo1b, NM2A, Myo6, Myo9b, Myo10, Myo18a, and NM2A in PC-3 and LNCaP cells ([Figures 2](#fig2){ref-type="fig"}A and 2B) showed similar trends in protein expression levels.

In PC-3 cells, high endogenous levels of Myo10 were associated with a high number of filopodia ([Figures 2](#fig2){ref-type="fig"}C and 2D), in which Myo10 was localized to the tips ([Figure 2](#fig2){ref-type="fig"}F), as expected from its known role in filopodium formation ([@bib5], [@bib6]). In contrast, both filopodium number and Myo10 expression levels were low in LNCaP cells ([Figure 2](#fig2){ref-type="fig"}C), staining was diffuse, and Myo10 was often absent from filopodial tips ([Figures 2](#fig2){ref-type="fig"}E and 2F). Upregulation of Myo10 in breast cancer cells has been linked to expression of mutant p53 ([@bib3]). However, LNCaP cells are p53 wild-type, and PC-3 cells are p53-null ([@bib14]), suggesting that, in this case, there is no link between Myo10 overexpression and expression of mutant p53. In DU145 cells, which do express mutant p53, Myo10 expression is slightly higher, and numbers of filopodia are increased compared with LNCaP cells ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B), but both are lower compared with PC-3 cells.

Myo1b localized to organelles in both cell types ([Figures 2](#fig2){ref-type="fig"}D and 2E), as expected from its roles in trafficking of endosomes, multivesicular bodies, and lysosomes ([@bib16], [@bib33], [@bib35]). Higher Myo1b expression in PC-3 cells was associated with an additional localization of Myo1b to actin-rich structures at the plasma membrane and filopodia ([Figure 2](#fig2){ref-type="fig"}D), consistent with an earlier study ([@bib39]). Myo9b and Myo18a were both enriched in membrane ruffles/lamellipodia in PC-3 cells ([Figure 2](#fig2){ref-type="fig"}D), consistent with Myo18a's role in modifying actin organization in the lamellipodium ([@bib24]) and Myo9b's role in cell polarity and recruitment of RhoGAP to the lamellipodium ([@bib21]). Staining for both was diffuse in LNCaP cells.

The higher endogenous expression levels of Myo1b, Myo9b, and Myo10 in more metastatic cell types/tissue suggested that they all contribute to the cellular phenotype of metastatic cells. We therefore used siRNA knockdown (KD) to determine the effects of reducing their expression levels in PC-3 cells on cell morphology and cell migration. We also investigated Myo18a because the interaction of Myo18a regulates NM2A filaments ([@bib9]) and, therefore, may also influence cell migration and phenotype.

Knockdown of Myo1b, Myo9b, Myo10, and Myo18a Results in Isoform-Specific Changes in Cell Morphology, Cell Migration, and Actin Bundle Organization in PC-3 Cells {#sec2.2}
----------------------------------------------------------------------------------------------------------------------------------------------------------------

siRNA-mediated KD for 72 hr significantly reduced expression levels of each myosin isoform in PC-3 cells ([Figure 3](#fig3){ref-type="fig"}A) and altered their morphology ([Figure 3](#fig3){ref-type="fig"}B). The spread area of the cells increased up to 3-fold ([Figure 3](#fig3){ref-type="fig"}C). KD of Myo10, but not Myo1b, Myo9b, or Myo18a, also significantly reduced the numbers of filopodia ([Figure 3](#fig3){ref-type="fig"}D). Although the increase in cell area in Myo10 KD cells could be explained by the reduction in filopodia, as reported for COS-7 and HeLa cells ([@bib10]), it does not explain the increased cell area for Myo1b, Myo9b, and Myo18a KD cells, where filopodia are still present.

Myo9b and Myo10 were most important for PC-3 cell migration in 2D. Knockdown of Myo9b and Myo10 both significantly reduced cell speed ∼2-fold in a 2D random migration assay ([Figures 3](#fig3){ref-type="fig"}E and 3F). Directional persistence was increased slightly for Myo9b KD cells but unaltered for Myo10. In contrast, knockdown of Myo1b and Myo18a did not affect speed in 2D random migration assays ([Figures 3](#fig3){ref-type="fig"}E and 3F). Knockdown of Myo18a significantly reduced directional persistence in 2D ([Figures 3](#fig3){ref-type="fig"}E and 3G), indicating that these cells are less able to polarize. However, cell migration was inhibited for each myosin in a circular invasion assay ([Figure 3](#fig3){ref-type="fig"}H) that closely mimics 3D invasion ([@bib45]). Staining for F-actin in circular migration assays ([Figure 3](#fig3){ref-type="fig"}I) showed an increase in actin stress fibers for cells at the border for each myosin knockdown compared with controls.

We also observed distinct changes in the acto-myosin organization following KD of each myosin. Control PC-3 cells ([Figures 4](#fig4){ref-type="fig"}A and 4B) contained few F-actin stress fibers, and NM2A staining was mostly localized to the lamellae. A marked increase in centripetal F-actin fibers running parallel to the plasma membrane in the lamella associated with NM2A filaments was characteristic of Myo18a KD ([Figures 4](#fig4){ref-type="fig"}A and 4B). The appearance of sparse, long stress fibers, associated with NM2A and extended along the length of the cells, was characteristic of Myo1b KD ([Figures 4](#fig4){ref-type="fig"}A--4C). A line profile analysis of the frequency of actin bundles in the lamellae of KD cells showed that the frequency of bundles was reduced significantly (2.1 ± 0.1 bundles/μm, mean ± SEM, n = 9) compared with controls (2.6 ± 0.2 bundles/μm, mean ± SEM, n = 9, p \< 0.5%) ([Figures 4](#fig4){ref-type="fig"}A and 4B), suggesting that the actin cytoskeleton is being re-organized. Myo9b KD cells contained a distinctive actin-rich area at the cell periphery from which NM2A was largely absent, in addition to an increase in stress fibers ([Figures 4](#fig4){ref-type="fig"}A and 4B). Myo10 KD cells showed loss of filopodia and the appearance of distinctive actin bundles in the central region of the cell ([Figures 4](#fig4){ref-type="fig"}A and 4B).

Changes to the F-actin organization were associated with formation of focal adhesions at the edges of the cells, consistent with a more spread cell phenotype ([Figure 4](#fig4){ref-type="fig"}C). Knockdown of Myo1b, Myo10, or Myo18a did not change phosphorylation levels of myosin light chain (MLC) ([Figure 4](#fig4){ref-type="fig"}D), suggesting that NM2A is re-organized rather than activated as a result of their knockdown. Myo9b KD did increase MLC phosphorylation ∼2-fold in cells, and this is likely to contribute to the actomyosin re-organization observed ([Figure 4](#fig4){ref-type="fig"}D).

Discussion {#sec3}
==========

These data show that Myo10, Myo9b, and Myo1b are overexpressed in more highly metastatic cell lines and in metastatic tissue. High levels of Myo10 in PC-3 cells are linked to high numbers of filopodia, and high levels of Myo9b are linked to low levels of stress fibers. Both isoforms contribute to a more migratory phenotype, as shown by immunostaining, cell migration, and KD experiments. Myo1b and Myo18a influence cell morphology and actin organization but have little effect on migration in 2D, whereas all four isoforms inhibit cell migration in invasion assays. Therefore, changes in expression of several myosin isoforms may contribute to metastasis in prostate cancer.

Our finding that Myo10-dependent filopodia are likely to be important in prostate cancer agrees with recent similar findings for breast cancer metastasis ([@bib3], [@bib13]) and non-small lung cell cancer ([@bib37]). Filopodia are important but not absolutely required for cell migration because Myo10 KD cells can migrate in 2D but with a reduced speed, and other cells lacking filopodia can migrate ([@bib25]). The increased cell area resulting from Myo10 KD agrees with previous findings ([@bib10]). The central actin bundles in Myo10 knockdown cells are reminiscent of actin bundles in filopodia. Fascin is also required for filopodial formation ([@bib41]), its overexpression results in multiple filopodia ([@bib41]), and fascin levels are also upregulated in prostate cancer ([@bib17]). Myo10 KD may lead to actin bundling in the cell body by excess (non-phosphorylated) fascin. The role of two filopodial proteins, Myo10 and fascin, in prostate (and other) cancers suggest that filopodium formation is key for metastasis. Myo10 has also been implicated in integrin-mediated adhesion, and any reduction in adhesion resulting from its KD could disrupt signaling to the actin cytoskeleton and, therefore, indirectly result in changes in actin organization.

High levels of Myo9b expression in PC-3 cells are likely to contribute to their lack of stress fibers and, therefore, to enhanced migration. The RhoGTPase-activating domain in Myo9b inhibits Rho, reducing the downstream activity of ROCK (RhoKinase), thereby increasing MLC phosphatase activity, reducing MLC phosphorylation ([@bib34], [@bib44]), and, therefore, reducing actin stress fiber formation. Knockdown of Myo9b is therefore expected to increase MLC phosphorylation and stress fiber formation, as we observed. In agreement with our findings, a previous report has shown that cell migration was reduced and MLC phosphorylation increased in macrophages isolated from Myo9b knockout mice ([@bib21]). Myo9b has also been implicated in an increased risk of esophageal cancer ([@bib26]).

The high levels of Myo1b in PC-3 cells and effects of knockdown on 3D invasion, cell shape, and morphology suggest that it, too, has a role in prostate cancer. Myo1b has also been implicated in non-small-cell lung cancers ([@bib29]). Myo1b (Myr1/MM1α; [@bib20]) regulates actin assembly in vesicular transport (post-Golgi carriers \[[@bib2]\] and endocytic organelles \[[@bib16], [@bib33]\]), and it maintains cortical tension at the plasma membrane, where it specifically associates with dynamic, non-tropomyosin-containing actin filaments ([@bib15], [@bib39]). High endogenous levels of Myo1b in more highly metastatic cells might therefore increase cortical tension, allowing cells to move through stiff extracellular matrices in vivo, perhaps explaining why knockdown of Myo1b only affects migration in 3D but not 2D.

Myo18a could contribute to metastasis in prostate cancer. The re-organization of actin and NM2A in Myo18a KD cells may arise from its interaction with non-muscle myosin 2 (NM2). NM2 forms short filaments (∼300 nm long) containing ∼20 molecules ([@bib8]). The assembly/disassembly of non-muscle myosin 2 filaments is dynamic ([@bib36]) and regulated by many different pathways ([@bib40]). Myo18a and NM2A can form mixed bipolar filaments in vitro that are smaller that pure NM2A filaments ([@bib9]). The re-organization of NM2A we observed after knocking down Myo18a, without a change to levels of light chain phosphorylation, supports the idea that an interaction between Myo18a and NM2A modulates NM2A filament formation and organization in PC-3 cells.

Therefore, Myo1b, Myo9b, Myo10, and Myo18a each contribute to the morphology and migration of more highly metastatic PC-3 cells, with each myosin having a specific effect on actin organization. Misregulation of their expression in cells with metastatic potential may allow them to work in concert to generate a torpedo-shaped cell with multiple protrusions that is better able to migrate through a 3D matrix and, therefore, more able to metastasize. Many different drugs have now been developed that can inhibit specific myosin isoforms, including those in classes 1, 2, 5, and 6 ([@bib11]). Developing drugs to block specific myosin functions could be useful in preventing metastasis. Importantly, these results emphasize that myosin not only uses actin as tracks to walk along but that it is able to actively drive actin organization in cells.

Experimental Procedures {#sec4}
=======================

Cell Culture {#sec4.1}
------------

LNCaP, DU145, and PC-3 cells (from the ATCC) were grown in RPMI 1640 medium with GlutaMAX (Gibco, Life Technologies) supplemented with 10% heat-inactivated fetal bovine serum (FBS) and penicillin-streptomycin. 1535NP and CT cells ([@bib12]) were a gift from Suzanne Topalian (Johns Hopkins University School of Medicine). They were grown in keratinocyte medium (Gibco, Life Technologies) supplemented with 10% heat-inactivated FBS, 1% L-glutamate, antibiotics, bovine pituitary extract, and epidermal growth factor.

Antibodies and Reagents {#sec4.2}
-----------------------

The antibodies used were as follows: Myo6 (H-215, Santa Cruz Biotechnology); Myo10 (HPA024223, Sigma); total ERK (p44/42 mitogen-activated protein kinase \[MAPK\], Cell Signaling Technology); Myo18a, a gift from Prof. Yu and Dr. Hsu (Chang Gung University, Taiwan; [@bib24]) or from Genscript; NM2A (PRB-440P, Covance); paxillin (SAB4502553, Sigma); Myo1b (HPA013607, Sigma); phospho-myosin light chain (Cell Signal); Myo9b (Proteintech); and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Abcam). HRP-conjugated secondary antibodies and fluorescent phalloidin were from Sigma, and fluorescent secondary antibodies were from Molecular Probes.

Transfections {#sec4.3}
-------------

siGENOME SMARTpool siRNA (GE Healthcare, Dharmacon) was used to silence myosins in PC-3 cells. Cells were seeded at a density of 20,000 cells/ml in growth media and allowed to adhere and grow overnight. Lipofectamine RNAiMAX reagent (Invitrogen, Life Technologies) was used for transfections. Maximum KD was achieved after 72 hr.

PCR {#sec4.4}
---

The RNeasy mini kit (QIAGEN) was used to extract cellular RNA. cDNA was synthesized using avian myeloblastosis virus (AMV) reverse transcriptase. RT-PCR was used to detect which myosin isoforms were expressed ([Table S1](#mmc1){ref-type="supplementary-material"}). Real-time PCR using SYBR Green was used to investigate the expression levels of expressed myosins (see [Table S2](#mmc1){ref-type="supplementary-material"} for primer sequences). Data analysis was performed using a Bio-Rad system and software.

Immunoblotting {#sec4.5}
--------------

Cells were lysed (30 min, 4°C) in lysis buffer (150 mM NaCl, 0.05 M Tris \[pH 8\], 1% Triton X-100, and 1 mM EDTA \[pH 8\] with protease inhibitor cocktail (Thermo Scientific). Lysates were clarified by centrifugation, protein content was quantified by bicinchoninic acid (BCA) assay, and then samples were mixed with 2× Laemmli buffer for use in protein gels (4%--20% or 7.5%) and blots. Chemiluminescence detection (Supersignal West Pico, Thermo Scientific) used multiple exposures to ensure signal linearity. If required, membranes were stripped using Restore western blot stripping buffer (Thermo Scientific) and re-probed.

Immunostaining {#sec4.6}
--------------

Cells were grown on glass coverslips, fixed with 2% paraformaldehyde in PBS, and stained using standard procedures ([@bib38]). Cells were imaged using a DeltaVision deconvolution microscope or Zeiss880 Airyscan.

Migration Assays {#sec4.7}
----------------

For 2D assays, cells were plated onto a glass-bottomed 96-well plates, transfected with non-targeting siRNA or with myosin KD siRNA (three replicates each), serum-starved 48 hr later for 24 hr, and then treated with hepatocyte growth factor (HGF) (25 ng/ml) for filming. A minimum of three fields from each replicate was selected for imaging, over 14 hr at 5-min intervals using differential interference contrast (DIC) optics, and a 20× lens (512 × 512 total pixel size, 2 × 2 binning) on a DeltaVision system. Cell migration was analyzed using ImageJ software (MTrackJ plugin). To perform the 3D-like circular invasion assay ([@bib45]), cell-free space was created using cell stoppers (Ibidi). After removing the stopper, cells were covered with a thin layer of Matrigel (4 mg/ml) and normal medium and allowed to grow and migrate for another 24--48 hr. Cells were then fixed in 2% paraformaldehyde (PFA) and stained.

Data Analysis {#sec4.8}
-------------

Immunoblots and digitized images of immunostained cells were analyzed using ImageJ. GraphPad Prism 5.0 was used to analyze data. Data are presented as mean ± SD for at least three separate experiments (n ≥ 3). A two-way ANOVA was used to compare differences between groups, and statistical significance was accepted for p ≤ 0.05.
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![Myosin Expression Profiles in Tumors and Prostate Cancer Cell Lines\
(A) Comparison of the expression levels for 12 of the myosin isoforms expressed by LNCaP and PC-3 cells, detected by qPCR. Data are presented as mean ± SD (n = 3).\
(B) Comparison of the expression levels for six myosin isoforms expressed by a pair of matched (normal \[1535NP\] and cancerous \[1535CT\]) prostate cancer cell lines, detected by qPCR. Data are presented as mean ± SD (n = 3).\
(C) In silico analysis of the mRNA expression levels for eight myosin isoforms in 171 (GEO: [GSE6919](ncbi-geo:GSE6919){#intref0015}) prostate tumor samples. Data are shown as the log2 expression ratio. Clinical tumor classification and number of samples are indicated.\
^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.](gr1){#fig1}

![Expression and Localization of Myosin Isoforms in LNCaP and PC-3 Cells\
(A and B) Example immunoblots (A) showing the variation in expression levels for five myosin isoforms in PC-3 and LNCaP cells. Molecular markers (in kilodalton) are shown on the right. Anti-Myo18a shows a single band with a molecular weight close to 230 kDa, suggesting that only the α isoform is expressed ([@bib28]). The results are quantified in (B). Data are presented as mean ± SD (n = 3). Expression levels were compared with total p44/p42 MAPK (ERK) for all isoforms except Myo9b, for which GAPDH was used. GAPDH gave similar results as ERK as a loading control.\
(C) Quantification of numbers of filopodia in LNCaP and PC-3 cells (n = 20).\
(D and E) Maximum intensity projection images for PC-3 (D) and LNCaP (E) cells immunostained for F-actin (red) and either Myo1b, Myo9b, Myo10, or Myo18a (green). The arrows in (D) indicate Myo1b localization within filopodia, Myo9b in actin rich protrusions, Myo10 at filopodial tips, and Myo18 in actin-rich lamellae. The arrows in (E) indicate Myo1b localization to vesicles and lack of Myo9b in actin-rich protrusions. Merged images include nuclear staining using DAPI (blue). Scale bar, 30 μm.\
(F) Many filopodia, and Myo10 at their tips PC-3 cells, contrasted with few filopodia with lack of Myo10 localization in LNCaP cells.\
^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.](gr2){#fig2}

![Knockdown of Myosin 1b, 9b, 10, and 18a Affects Morphology and Cell Migration of PC-3 Cells\
(A) KD of Myo1b, Myo9b, Myo10, or Myo18a in PC-3 cells analyzed by immunoblotting after 72 hr confirms that myosin levels are reduced significantly. Loading control: total ERK or GAPDH.\
(B) Representative fields showing control and myosin-depleted PC-3 cells stained for F-actin using fluorescent phalloidin, obtained by tiling using the ×40 objective on the Zeiss LSM 880. Images are shown in reverse contrast. Arrowheads show prominent stress fibers (Myo1b KD), peripheral high-density actin staining (Myo9b KD), central stress fiber bundles (Myo10 KD), and increased actin in lamellae (Myo18a KD).\
(C and D) Quantification of cell area (C) and number of filopodia (D) in control and myosin KD cells (n = 20). NT, control cells treated with non-targeting siRNA.\
(E) Representative tracks for individual cells during an overnight time-lapse microscopy experiment for control (treated with non-targeting siRNA) and Myo1b, Myo9b, Myo10, and Myo18a-KD cells after HGF stimulation. Each colored line represents the track taken by an individual cell in the field.\
(F and G) Quantification of speed (F) and directional persistence (G) of cell migration (n = 50 cells). Data were plotted as box-and-whisker plots, with whiskers showing maximum and minimum values.\
(H) Circular invasion assay showing cells stained for F-actin and nuclei (DAPI). The dashed line marks the border of cell-free space that was created by stoppers before their removal. Scale bar, 100 μm and 90 μm (Myo18a KD).\
(I) Magnified images of cells at the border of the cell-free space stained for F-actin. Scale bar, 10 μm.\
^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.](gr3){#fig3}

![Knockdown of Myosin 1b, 9b, 10, and 18a Affects Focal Adhesion and Actin and NM2A Organization in PC-3 Cells\
(A and B) Control cells treated with non-targeting siRNA and myosin-depleted cells co-stained for F-actin (red) and NM2A (green) (A). An enlarged view of the region in the boxed area in (A) is shown in (B). Arrowheads indicate F-actin structures in KD cells. Scale bars, 5 μm (A) and 2 μm (B).\
(C) Control NT cells and myosin-depleted cells co-stained for F-actin (red) and focal adhesions using paxillin (green). Arrowheads indicate focal adhesions at the ends of F-actin bundles in KD cells Scale bar, 30 μm.\
(D) Immunoblotting for phosphorylated myosin light chain (pMLC) and ERK or GAPDH (loading control) in control and KD cells. Quantification of the control and Myo9b KD blot shown here showed a 1.8-fold increase in pMLC in KD compared with NT cells. UT, untreated.](gr4){#fig4}
